Dulaglutide

ATC code
A10BJ05
Therapeutic class
Glucagon-like peptide-1 (GLP-1) analog · Glucagon-like peptide-1 (GLP-1) analog
Forms
pre-filled pen solution for injection
Brand names
Trulicity (EU) · Trulicity (ES)
Overall confidence
high

Regulatory sources consulted

Approved indications

Contraindications

Absolute

  • Hypersensitivity to the active substance or to any of the excipients.
  • Personal or family history of medullary thyroid carcinoma (MTC) or in patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).

Clinical warnings

Drug interactions

Adverse events

Common (≥1%)

nausea · diarrhea · vomiting · abdominal pain · decreased appetite

Rare but serious

acute pancreatitis · anaphylactic reactions · angioedema · intestinal obstruction

Pregnancy and lactation

Use during pregnancy is not recommended due to reproductive toxicity in animals. Should not be used during breast-feeding as it is unknown if it is excreted in human milk.